Added to YB: 2025-07-23
Pitch date: 2025-07-21
ABVX [bullish]
ABIVAX Société Anonyme
+570.79%
current return
Author Info
No bio for this author
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 547.1M
Pitch Price
EUR 8.90
Price Target
101.40 (+70%)
Dividend
N/A
Sector
Biotechnology
Category
special_situation
ABVX: High-Stakes UC Readout with 10x Potential and Deeply Discounted Odds
ABVX: Ulcerative colitis Ph3 readout August could bring 5-10x upside. Market pricing high failure odds despite promising data: strong maintenance efficacy (55% remission rate), Ph3 response rate tracking higher than Ph2b (53.7% vs 51.2%). Pre-disclosed enrollment data suggests 13-15% remission delta. 90%+ downside if fails. Recent UC buyouts averaged $8B vs $630M current cap.
Read full article (19 min)